Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Endocrine Disorders
Published in: BMC Endocrine Disorders 1/2024

Open Access 01-12-2024 | Glucocorticoid | Research

Combined glucocorticoids and cyclophosphamide in the treatment of Graves’ ophthalmopathy: a systematic review and meta-analysis

Authors: Qilang Xiang, Mengling Yang, Wenxuan Luo, Yuzi Cao, Shiquan Shuai, Xin Wei, Anji Xiong

Published in: BMC Endocrine Disorders | Issue 1/2024

Login to get access

Abstract

Purpose

To evaluate the efficacy and safety of combined glucocorticoids (GCs) and cyclophosphamide (CYC) treatment in Graves’ ophthalmopathy (GO).

Methods

We searched PubMed, Embase, Cochrane Library, and four Chinese databases (Chinese National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), WanFang, and SinoMed) for any published randomized controlled trials (RCTs) produced from inception to December 1, 2023. Articles obtained using appropriate keywords were selected independently by two reviewers according to the established inclusion and exclusion criteria.

Findings

We retrieved 1120 records which were eventually reduced to 13 RCTs which were then included in this evaluation. Pooled results indicated that the experimental group (CYC/GCs) showed a higher response rate than control group (GCs or negative control) (RR 1.27; 95% confidence interval 1.19 to 1.37). The subgroup analysis showed that the difference in response rates among treatment protocols (CYC/P, CYC/MPS, CYC/DEX) was not statistically significant (p = 0.23).

Implications

The combination of GCs and CYC could be recommended as a therapeutic option for GO, especially in patients who experience recurrence after a withdrawal GCs, have a poor response to GCs, or cannot obtain monoclonal antibody agents for various reasons.
Appendix
Available only for authorised users
Literature
1.
2.
Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, Kahaly GJ, Ludgate M. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020;16(2):104–16.CrossRefPubMed
3.
Salvi M. Immunotherapy for Graves’ ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):409–14.CrossRefPubMed
4.
Khong JJ, McNab AA, Ebeling PR, Craig JE, Selva D. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms. Br J Ophthalmol. 2016;100(1):142–50.CrossRefPubMed
5.
Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2014;55(3):1735–48.CrossRefPubMedPubMedCentral
6.
Hwang CJ, Afifiyan N, Sand D, Naik V, Said J, Pollock SJ, Chen B, Phipps RP, Goldberg RA, Smith TJ, et al. Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci. 2009;50(5):2262–8.CrossRefPubMed
7.
van Steensel L, Paridaens D, Schrijver B, Dingjan GM, van Daele PLA, van Hagen PM, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik WA. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves’ ophthalmopathy. Invest Ophthalmol Vis Sci. 2009;50(7):3091–8.CrossRefPubMed
8.
Smith TJ. Janssen JAMJL: Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy. Endocr Rev. 2019;40(1):236–67.CrossRefPubMed
9.
Wiersinga WM. Advances in treatment of active, moderate-to-severe Graves’ ophthalmopathy. Lancet Diabetes Endocrinol. 2017;5(2):134–42.CrossRefPubMed
10.
11.
Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185(4):G43–67.CrossRefPubMed
12.
13.
Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13.
14.
Barshes NR, Goodpastor SE, Goss JA. Pharmacologic immunosuppression. Front Biosci. 2004;9:411–20.CrossRefPubMed
15.
de Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44(11):1135–64.CrossRefPubMed
16.
Kwon CH, Borch RF, Engel J, Niemeyer U. Activation mechanisms of mafosfamide and the role of thiols in cyclophosphamide metabolism. J Med Chem. 1987;30(2):395–9.CrossRefPubMed
17.
Sladek NE. Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo. Cancer Res. 1973;33(6):1150–8.PubMed
18.
Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int. 2002;61(4):1495–501.CrossRefPubMed
19.
Fu M, Chang Y, Li M, Luo X, Yu S. Small dose prednisone and cyclohosphamide for treatment of hyperthroid infiltrative exophthalmos [In Chinese]. Chin J Endocrinol Metabol. 1993;03:44.
20.
Zhou X, Gu Y, Zhang Y, Ma X, Wei R. Immunosuppressive agents pulse therapy on ocular surface influences in thyroid associated ophthalmopathy [In Chinese]. Ophthalmol China. 2016;25(01):40–4.
21.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.CrossRefPubMedPubMedCentral
22.
Zhang Y, Wang Q, Zhimin L, Xiaoling Y. Different usages of immunosuppressive agents for treating thyroid-associated eye disease [In Chinese]. Shanghai Med J. 2005;12:1033–6.
23.
Wang Y, Fu L, Lu T, Zhang G, Zhang J, Zhao Y, Jin H, Yang K, Cai H. Clinicopathological and Prognostic Significance of Long Non-coding RNA MIAT in Human Cancers: A Review and Meta-Analysis. Front Genet. 2021;12:729768.CrossRefPubMedPubMedCentral
24.
Wang Y, Jiang X, Zhang D, Zhao Y, Han X, Zhu L, Ren J, Liu Y, You J, Wang H, et al. LncRNA DUXAP8 as a prognostic biomarker for various cancers: A meta-analysis and bioinformatics analysis. Front Genet. 2022;13:907774.CrossRefPubMedPubMedCentral
25.
Shi Y, Liu Z, Gu M, Zou J, Xu J, Peng L, Lin L. Treatment for thyroid associated ophthalmopathy with retrobublar injection of immunosuppressive agents [In Chinese]. Shanghai Med J. 2004;07:473–5.
26.
Liu Z, Liu Z. Clinical Study on cyclophosphamide combined with methylprednisolone for Graves’ ophthalmopathy [In Chinese]. Chin Ophthalmic Res. 2005;03:336.
27.
Ruan Y, Du J, Wang B. Therapeutic effect analysis and nursing care of Graves ophthalmopathy treated by retrobulbar injection of different immunosuppressants [In Chinese]. Chin J Pract Nurs. 2006;01:34–5.
28.
Tang Y, Zheng W, Wang J. Efficacy of Prednisone Plus Cyclophosphamide in Treatment of Infiltrative Exophthalmos [In Chinese]. Am J Chin Clin Med. 2006;8:327–30.
29.
Su C. Effect of cyclophosphamide combined with methylprednisolone on diabetic patients with toxic goiter endocrine ophthalmopathy [In Chinese]. Contemp Med Symposium. 2014;12(16):245–6.
30.
Dai Y, Geng Y, Liu J, Zhang J, Meng X, Fang H. Clinical Study on Immunosuppressive Stosstherapy for Thyroid Associated Ophthalmopathy [In Chinese]. Med Recapitulate. 2015;21(05):931–2.
31.
Yufeng W. Efficacy of Prednisone Plus Cyclophosphamide in Treatment of Infiltrative Exophthalmos of Hyperthyroidism [In Chinese]. Chin Contin Med Educ. 2015;7(30):157–8.
32.
Wen J, You Y, Yang J, Jiang Y, Hong M, Liang G. Effect of immunosuppressive pulse therapy on inflammatory factors and immune function in patients with thyroid-associated ophthalmopathy [In Chinese]. Chin J Control Endemic Disenaces. 2016;31(06):684–5.
33.
Gao X. Evaluation of the effect of immunosuppressant pulse therapy on improving ocular surface symptoms in thyroid-associated ophthalmopathy [In Chinese]. Chin Foreign Med Res. 2018;16(11):40–2.
34.
Liang L. Therapeutic effect of cyclophosphamide combined with methylprednisolone on Graves’ opathalmopathy complicated by diabetes mellitus [In Chinese]. Pract Clin J Integr Tradit Chin Western Med. 2020;20(02):12–3.
35.
Cajal U, Zang T. Effect of high-dose methylprednisolone combined with cyclophosphamide in treatment of infiltrative exophthalmos of hyperthyroidism [In Chinese]. Electron J Clin Med Lit. 2020;7(01):145.
36.
Wang X, Wang X, Guo T, Chen T. Study on the clinical efficacy of prednisone acetate + cyclophosphamide in the treatment of hyperthyroidism with exophthalmos and the changes of serum TRAb and IL-1 [In Chinese]. J Clin Exp Med. 2021;20(02):187–90.
37.
Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320–32.CrossRefPubMed
38.
Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21(2):168–99.PubMed
39.
Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Veronesi G, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97(12):4454–63.CrossRefPubMed
40.
41.
Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med. 2020;382(4):341–52.CrossRefPubMed
Metadata
Title
Combined glucocorticoids and cyclophosphamide in the treatment of Graves’ ophthalmopathy: a systematic review and meta-analysis
Authors
Qilang Xiang
Mengling Yang
Wenxuan Luo
Yuzi Cao
Shiquan Shuai
Xin Wei
Anji Xiong
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Glucocorticoid
Published in
BMC Endocrine Disorders / Issue 1/2024
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-024-01545-0

Other articles of this Issue 1/2024

BMC Endocrine Disorders 1/2024 Go to the issue

Research

Comparative effect of physical health training and psychological training of the theory of reasoned action (TRA) model on the life quality of patients with diabetes in Tehran, Iran: utilization of message texting

Correction

Correction: The association between creatinine to body weight ratio and the risk of progression to diabetes from pre-diabetes: a 5-year cohort study in Chinese adults

Research

Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Research

Therapeutic plasma exchange decreases serum triglyceride level rapidly and reduces early recurrence rate but no advantages in improving outcomes for patients with hyperlipidemic acute pancreatitis: a retrospective propensity score matching analysis based on twenty year’s experience

Study Protocol

Summary of clinical investigation plan for The DIATEC trial: in-hospital diabetes management by a diabetes team and continuous glucose monitoring or point of care glucose testing – a randomised controlled trial

Research

Dietary amino acid patterns and cardiometabolic risk factors among subjects with obesity; a cross-sectional study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits